Meeting of the International BFM Acute Myeloid Leukemia (AML) Relapse Working Group February 10, 2011

The meeting of the International BFM (I-BFM) AML-Relapse working group aims to highlight uniform approaches in research and clinical trials related to the relapse of AML to ensure large enough data sets, reproducibility of data and expertise in demanding techniques. The AML-Relapse working group is not officially part of the I-BFM Study Group but is engaged with demanding methodological issues.

Robert Lechleider, Director Clinical Development, will present on the topic of "Moxetumomab Pasudotox."